The No. 1 challenge the biopharmaceutical industry faces is public distrust, according to a survey of STAT plus subscribers, conducted by STAT.
Public distrust trumped several other challenges, including regulatory obstacles or the difficulty of developing drugs. The distrust largely stems from the large drugmaker profits and increasing drug prices, the survey found..
The survey, though a small sample size of 100, adds to the reality that most consumers don't trust the pharmaceutical industry.
According to a 2016 Harris Poll asking 1,018 U.S. adults their opinions about the healthcare industry, just 9 percent of U.S. customers believe pharma companies put patients over profits.
Read results from the full survey here.